Nucleix
PrivateLast Round
Series C
Extension
Dec 31, 2021
Total Funding Raised
$143.45M
Company Overview
Nucleix is a biotechnology company that develops non-invasive molecular diagnostic tests to enhance the accuracy and effectiveness of cancer detection through the use of DNA methylation patterns and proprietary biomarker assays.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nucleix Comparables
Compare Nucleix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pacific Edge Limited | 82% | |
| Pangea Laboratory | 81% | |
| MDxHealth | 78% | |
Nucleix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Dec 31, 2021 | ||||
| Series C | Apr 7, 2021 | ||||
| VC Round | Jul 1, 2019 | ||||
| Grant | Jul 30, 2018 | ||||
| VC Round | May 23, 2016 | ||||
Grant | Mar 1, 2016 |
Key People
Founding team and executive leadership
Nucleix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Aurum Ventures | Series C |
| DSC Investment | Series C Extension, VC Round, Series C |
| RA Capital Management | Series C Extension, Series C |
| European Commission (Horizon Europe) | Grant |
| LYFE Capital | Series C Extension, Series C |
| Gefen Capital | Series C |
| OrbiMed | VC Round, Series C Extension, Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 25, 2025
Presenting Bladder EpiCheck data at the AUA 2025 conference.
- Dec 30, 2021
$22M round led by Sands Capital
Nucleix Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Nucleix's valuation, stock price, and market status.